2Seventy Bio Inc. - notizie pubblicate 191 - letture 4.074
2SEVENTY BIO INC.
UNAUDITED PRO FORMA FINANCIAL INFORMATION - Form 8-K
Unaudited pro forma financial information on april 1, 2024 (the "closing date"), 2seventy bio, inc. ("2seventy", the "company" "we" or " ...
2SEVENTY BIO INC.
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
2seventy bio announces completion of oncology and autoimmune pipeline divestiture to regeneron april 1, 2024 at 7:30 am edt pdf version - company now exclusively focused on develop ...
2SEVENTY BIO INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
2SEVENTY BIO INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
2SEVENTY BIO INC.
Initial Statement of Beneficial Ownership - Form 3
Ownership submission form 3 united states securities and exchange commission washington, d.c. 20549initial statement of beneficial ownership of securities filed pursuant to section ...
2SEVENTY BIO INC.
Management Change/Compensation - Form 8-K
2seventy bio announces appointments of eli casdin and charles newton to board of directors cambridge, mass.- march 20, 2024 - 2seventy bio, inc. (nasdaq: tsvt), announced today tha ...
2SEVENTY BIO INC.
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
2seventy bio announces appointments of eli casdin and charles newton to board of directors march 20, 2024 at 5:04 pm edt pdf version cambridge, mass.--(business wire)--mar. 20, 202 ...
2SEVENTY BIO INC.
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy - Form 8-K
Fda advisory committee votes in favor of bristol myers squibb's and 2seventy bio's abecma for triple-class exposed multiple myelomain earlier lines of therapy the supplemental biol ...
2SEVENTY BIO INC.
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
Fda advisory committee votes in favor of bristol myers squibb's and 2seventy bio's abecma for triple-class exposed multiple myeloma in earlier lines of therapy march 15, 2024 at 6: ...
2SEVENTY BIO INC.
Annual Report for Fiscal Year Ending December 31, 2023 (Form 10-K)
Tsvt-20231231 united states securities and exchange commission washington, d.c. 20549 form 10-k (mark one) ☒ annual report pursuant to section 13 or 15(d) of the securities excha ...
2SEVENTY BIO INC.
New strategic path forward as Abecma-focused company announced in January 2024; on track to close Asset Sale of R&D pipeline to Regeneron in the first half of 2024 - Form 8-K
New strategic path forward as abecma-focused company announced in january 2024; on track to close asset sale of r&d pipeline to regeneron in the first half of 2024 u.s. food an ...
2SEVENTY BIO INC.
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
2seventy bio reports fourth quarter and full year 2023 financial results and recent operational progress march 5, 2024 at 7:00 am est pdf version new strategic path forward as abec ...
2SEVENTY BIO INC.
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
2seventy bio to report fourth quarter and full year 2023 financial results and participate in upcoming investor conferences march 1, 2024 at 7:00 am est pdf version cambridge, mass ...
2SEVENTY BIO INC.
2seventy bio to Participate in Upcoming Investor Conferences
2seventy bio to participate in upcoming investor conferences february 5, 2024 at 4:05 pm est pdf version cambridge, mass.--(business wire)--feb. 5, 2024-- 2seventy bio, inc. (nasda ...
2SEVENTY BIO INC.
Amendment to Current Report - Form 8-K/A
Tvst-20240129 united states securities and exchange commission washington, d.c. 20549 form 8-k/a (amendment no. 1) current report pursuant to section 13 or 15(d) of the securities ...
Per i consulenti finanziari
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti